Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

April 26 - 27, 2013

New York, New York
The Westin NY Times Square

Scientific Agenda

Friday, April 26, 2013

7:00 am

Registration

8:00 am

Introduction and pre-activity audience response survey (ARS)

Session I: Multiple Myeloma

Moderator: Robert Z. Orlowski, MD, PhD

8:05 am

Debate: How should high-risk smoldering multiple myeloma be managed?

Immediate treatment
David H. Vesole, MD, PhD

Watch and wait
Sagar Lonial, MD

8:35 am

Debate: What is the optimal induction therapy for newly diagnosed, transplant-eligible multiple myeloma?

Two-drug regimens
Tomer Mark, MD

Three-drug regimens
Kenneth C. Anderson, MD

Four-drug regimens
P. Leif Bergsagel, MD

9:15 am

Lecture: Novel agents for multiple myeloma currently in phase 3 clinical trials
Robert Z. Orlowski, MD, PhD

9:35 am

Coffee Break

9:55 am

Debate: Treatment for a transplant-eligible patient whose disease is resistant to frontline therapy

Switch to a different novel agent regimen
Kenneth C. Anderson, MD

Use a traditional cytotoxic chemotherapy regimen
Leif Bergsagel, MD

10:25 am

Debate: What is the optimal maintenance strategy for patients with multiple myeloma who achieve VGPR or better after autologous stem-cell transplant?

Observation
Tomer Mark, MD

Maintenance with a single agent
Sagar Lonial, MD

Maintenance with a doublet regimen
David H. Vesole, MD, PhD

11:05 am

Debate: Frontline therapy for transplant-ineligible myeloma patients

Lenalidomide/low-dose dexamethasone or bortezomib/dexamethasone
Robert Z. Orlowski, MD, PhD

Three-drug regimen followed by maintenance
Kenneth C. Anderson, MD

11:35 pm

Case Discussion and Q&A Session
Open discussion with faculty, and opportunity for attendees to present case-based questions from their own practice

11:55 am

Lunch with the Professors

Session II: Acute Leukemias

Moderator: David P. Steensma, MD

1:00 pm

Lecture: DNA sequencing in acute leukemia: How will it impact the community hematologist?
Lukas Wartman, MD

1:20 pm

Debate: Will FLT3 inhibitors improve outcomes in FLT3-mutated AML in the near future?

Yes
Gail Roboz, MD

No
Richard Stone, MD

1:50 pm

Lecture: Acute lymphoblastic leukemia in the adult – integrating novel agents into the current therapeutic platform
Lukas Wartman, MD

2:10 pm

Coffee Break

Session III: Chronic Lymphocytic Leukemia

Moderator: James M. Epstein, MD

2:30 pm

Lecture: Hairy-cell leukemia – diagnosis and therapy in the BRAF era
Robert J. Kreitman, MD

2:55 pm

Debate: Where should the novel B-cell receptor signaling pathway inhibitors be used in the long-term management of CLL?

They will become part of frontline regimens
David A. Rizzieri, MD

They will be reserved for second- or third-line therapy
Richard Furman, MD

Coffee Break

Session IV: Chronic Myeloid Leukemia

Moderator: David P. Steensma, MD

3:25 pm

Debate: Are there newly diagnosed CP-CML patients for whom imatinib is still the preferred frontline treatment?

Yes, imatinib is tried and true
Gail Roboz, MD

No, second-generation TKIs are preferable
Ellen K. Ritchie, MD

3:55 pm

Debate: Should ponatinib be moved to the front line in CP-CML or saved for patients who do not respond to other TKIs?

Frontline therapy
David P. Steensma

Second line or T315I mutations only
David A. Rizzieri, MD

4:25 pm

Closing Remarks

4:30 pm

Adjourn

Saturday, April 27, 2013

8:00 am

Introduction to day two and pre-activity audience response survey (ARS)

Session V: "Not so Benign" Hematology

Moderator: James M. Epstein, MD

8:05 am

Lecture: Aplastic anemia in the adult: Diagnosis, prognosis, and management
Jaroslaw Maciejewski, MD, PhD

8:30 am

Lecture: Thrombocytopenia in the intensive care unit – a diagnostic approach
Mrinal Patnaik, MD

8:55 am

Lecture: Hypercoagulable disorders: Evaluation and management
Kenneth Bauer, MD

9:20 am

Coffee Break

Session VI: Myelodysplastic Syndromes

Moderator: David P. Steensma, MD

9:40 am

Debate: Is there a role for TPO agonists in higher-risk MDS patients?

Yes
Mrinal Patnaik, MD

No
Amit Verma, MD, MS

10:10 am

Lecture: How I manage low to intermediate-1 risk MDS
David P. Steensma, MD

10:40 am

Lecture: New insights into the genetics of myelodysplastic syndromes and how they will impact therapy in the future
Lukas Wartman, MD

Session VII: Myeloproliferative Neoplasms

Moderator: James M. Epstein, MD

11:00 am

Debate: Is there a role for JAK2 inhibitors in polycythemia vera and essential thrombocythemia?

Yes
Ruben A. Mesa, MD

No
Richard Stone, MD

11:30 am

Lecture: Pearls of wisdom in the management of MPNs
Ruben A. Mesa, MD

11:50 am

Lunch with the Professors

Session VIII: Lymphoproliferative Diseases

Moderator: John P. Leonard, MD

12:50 pm

Debate: Should we put R-CHOP aside in favor of R-bendamustine as frontline therapy for follicular lymphoma?

Yes
Myron S. Czuczman, MD

No
John P. Leonard, MD

1:20 pm

Debate: What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy?

Observation
Jonathan Friedberg, MD

Rituximab maintenance
Morton Coleman, MD

Radioimmunotherapy
Matthew J. Matasar, MD

2:00 pm

Lecture: Novel agents for follicular and mantle-cell lymphomas
Andre P. Goy, MD

2:20 pm

Coffee Break

2:40 pm

Debate: What is the best approach for a 50-year-old patient with chemosensitive follicular lymphoma after multiple relapses?

Radioimmunotherapy
Matthew J. Matasar, MD

Novel agents
Myron S. Czuczman, MD

Stem-cell transplant
John P. Leonard, MD

3:20 pm

Debate: What is the best treatment for a patient with Hodgkin's lymphoma who relapsed after auto-SCT, received brentuximab vedotin, and has now achieved CR?

Continue with maintenance brentuximab vedotin
Jonathan Friedberg, MD

Observe until disease progression
Owen O’Connor, MD, PhD

3:50 pm

Debate: What is the best upfront treatment for mantle-cell lymphoma in a 60-year-old patient?

Chemoimmunotherapy followed by maintenance
Andre P. Goy, MD

Chemoimmunotherapy followed by auto-SCT
Myron S. Czuczman, MD

4:20pm

Lecture: How I treat newly diagnosed T-cell lymphoma
Owen O’Connor, MD, PhD

4:40 pm

Lecture: Double-hit lymphomas – what are they, and how should they be managed?
John P. Leonard, MD

5:00 pm

Adjourn